Immunological basis for the use of TNFα-blocking agents in ankylosing spondylitis and immunological changes during treatment

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Zou, Jiaxiang X ^a   Braun, Jürgen ^a   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

T cells; TNF in ankylosing spondylitis; TNF blockers and cytokine secretion

Indexed keywords

CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; DOWN REGULATION; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOWN-REGULATION; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0036399586     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. BEUTLER BA: The role of tumor necrosis factor in health and disease. J Rheumatol 1999; 26 (Suppl.) 57: 16-21.
2. FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
3. BUTLER DM, MAINI RN, FELDMANN M, BRENNAN FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6: 225-30.
4. LIPSKY PE, VAN DER HEIJIDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
5. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
6. PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
7. SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
8. YIN Z, SIEGERT S, NEURE L et al.: The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology (Oxford) 1999; 38: 1058-67.
9. RUDWALEIT M, SIEGERT S, YIN Z et al.: Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60: 36-42.
10. BRAUN J, YIN Z, SPILLER I et al.: Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999; 42: 2039-44.
11. RUDWALEIT M, SIEPER J, BRAUN J: Frequency of atopic diseases in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis (in press).
12. HOHLER T, SCHAPER T, SCHNEIDER PM, MEYER ZUM BUSCHENFELDE KH, MARKER-HERMANN E: Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1998; 41: 1489-92.
13. GRATACOS J, COLLADO A, FILELLA X et al.: Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-31.
14. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
15. BRAUN J, SIEPER J: Anti-TNFalpha: A new dimension in the pharmacotherapy of the spondyloarthropathies ? Ann Rheum Dis 2000; 59: 404-7.
16. ZOU JX, RUDWALEIT M, THIEL A, BRAUN J, SIEPER J: Downregulation of the non-specific and antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with infliximab. Arthritis Rheum 2001; 44: S236.
17. NIKOLAUS S, RAEDLER A, KUHBACKER T, SFIKAS N, FOLSCH UR, SCHREIBER S: Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000; 356: 1475-9.
18. CAMUSSI G, LUPIA E: The future role of anti-tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55: 613-20.
19. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
20. GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
21. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
22. COPE AP, LONDEI M, CHU NR et al.: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 749-60.
23. BAETEN D, VAN DAMME N, VAN DEN BOSCH F et al.: Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001; 60: 750-5.
24. PLEVY SE, LANDERS CJ, PREHN J et al.: A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-82.
25. AGNHOLT J, KALTOFT K: Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001; 15: 212-22.
26. PREHN JL, LANDERS CJ, TARGAN SR: A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells. J Immunol 1999; 163: 4277-83.
27. MAURICE MM, VAN DER GRAAFF WL, LEOW A, BREEDVELD FC, VAN LIER RA, VERWEIJ CL: Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 2166-73.
28. BERG L, LAMPA J, ROGBERG S, VAN VOLLENHOVEN R, KLARESKOG L: Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001; 60: 133-9.